Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids

Prostaglandins and Other Lipid Mediators

Volumn 82, Issue 1-4, 2007, Pages 19-29

  Medhora, Meetha ^a   Dhanasekaran, Anuradha ^a   Gruenloh, Stephanie K ^a   Dunn, Laurel K ^a   Gabrilovich, Michael ^a   Falck, John R ^b   Harder, David R ^a   Jacobs, Elizabeth R ^a   Pratt, Phillip F ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cardioprotection; COX inhibitors; DDMS; HET0016

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CASPASE 3; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; EPOXYICOSATRIENOIC ACID; ESSENTIAL FATTY ACID; GROWTH FACTOR; HET 0016; ICOSANOID; INDOMETACIN; LIPOXYGENASE; N HYDROXY N (4 BUTYL 2 METHYLPHENOL)FORMAMIDINE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANGIOGENESIS; APOPTOSIS; ARTERY ENDOTHELIUM; CATALYSIS; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; FATTY ACID METABOLISM; HEART PROTECTION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; REVIEW; TUMOR GROWTH;

8,11,14-EICOSATRIENOIC ACID; ACTINS; ALKANE 1-MONOOXYGENASE; ANIMALS; APOPTOSIS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONIC ACID; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; EPOXY COMPOUNDS; HUMANS; KIDNEY; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 33845313333     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2006.05.025     Document Type: Review

References (65)

1. Nie D., and Honn K.V. Eicosanoid regulation of angiogenesis in tumors. Semin Thromb Hemost 30 (2004) 119-125
2. Fischer S.M., Lo H.H., Gordon G.B., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25 (1999) 231-240
3. Harris R.E., Alshafie G.A., Abou-Issa H., and Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60 (2000) 2101-2103
4. Abou-Issa H.M., Alshafie G.A., Seibert K., Koki A.T., Masferrer J.L., and Harris R.E. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 21 (2001) 3425-3432
5. Kawamori T., Rao C.V., Seibert K., and Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58 (1998) 409-412
6. Marnett L.J., and Kalgutkar A.S. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci 20 (1999) 465-469
7. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
8. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
9. Hasegawa K., Ichikawa W., Fujita T., et al. Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer 37 (2001) 1469-1474
10. Pozzi A., Yan X., Macias-Perez I., et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 279 (2004) 29797-29804
11. Macias-Perez I.M., Breyer M.D., Carmosino M., Breyer R.M., and Pozzi A. Activation of the EP3 receptor leads to epithelial-like morphology in HEK cells. Winter Eicosanoid Conference (2006) 17
12. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Adenoma Prevention with Celecoxib (APC) Study Investigators Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
13. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
14. Gao X., Grignon D.J., Chbihi T., et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 46 (1995) 227-237
15. Nie D., Hillman G.G., Geddes T., et al. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 58 (1998) 4047-4051
16. Heslin M.J., Hawkins A., Boedefeld W., et al. Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann Surg 241 (2005) 941-946 discussion 946-7
17. Jiang J.G., Chen C.L., Card J.W., et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65 (2005) 4707-4715
18. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82 (2002) 131-185
19. Nguyen X., Wang M.H., Reddy K.M., Falck J.R., and Schwartzman M.L. Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol 276 (1999) R1691-R1700
20. Wang M.H., Stec D.E., Balazy M., et al. Cloning, sequencing, and cDNA-directed expression of the rat renal CYP4A2: arachidonic acid omega-hydroxylation and 11,12-epoxidation by CYP4A2 protein. Arch Biochem Biophys 336 (1996) 240-250
21. Helvig C., Dishman E., and Capdevila J.H. Molecular, enzymatic, and regulatory characterization of rat kidney cytochromes P450 4A2 and 4A3. Biochemistry 37 (1998) 12546-12558
22. Hoch U., Zhang Z., Kroetz D.L., and Ortiz de Montellano P.R. Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid omega-hydroxylases. Arch Biochem Biophys 373 (2000) 63-71
23. Chen P., Guo M., Wygle D., et al. Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 166 (2005) 615-624
24. Carroll M.A., Balazy M., Margiotta P., Huang D.D., Falck J.R., and McGiff J.C. Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides. Am J Physiol 271 (1996) R863-R869
25. Croft K.D., McGiff J.C., Sanchez-Mendoza A., and Carroll M.A. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol 279 (2000) F544-F551
26. Zhu D., Zhang C., Medhora M., and Jacobs E.R. CYP4A mRNA, protein, and product in rat lungs: novel localization in vascular endothelium. J Appl Physiol 93 (2002) 330-337
27. Ljubimov A.V., and Grant M.B. P450 in the angiogenesis affair: the unusual suspect. Am J Pathol 166 (2005) 341-344
28. Guo M., Roman R.J., Falck J.R., Edwards P.A., and Scicli A.G. Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A. J Pharmacol Exp Ther 315 (2005) 526-533
29. Amaral S.L., Maier K.G., Schippers D.N., Roman R.J., and Greene A.S. CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol 284 (2003) H1528-H1535
30. Jiang M., Mezentsev A., Kemp R., et al. Smooth muscle-specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circ Res 94 (2004) 167-174
31. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., Houliston R.A., Martin J., and Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 420 (1997) 28-32
32. Sa G., Murugesan G., Jaye M., Ivashchenko Y., and Fox P.L. Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. J Biol Chem 270 (1995) 2360-2366
33. Banan A., Zhang L.J., Shaikh M., Fields J.Z., Farhadi A., and Keshavarzian A. Key role of PLC-gamma in EGF protection of epithelial barrier against iNOS upregulation and F-actin nitration and disassembly. Am J Physiol Cell Physiol 285 (2003) C977-C993
34. Warner L.C., Hack N., Egan S.E., Goldberg H.J., Weinberg R.A., and Skorecki K.L. RAS is required for epidermal growth factor-stimulated arachidonic acid release in rat-1 fibroblasts. Oncogene 8 (1993) 3249-3255
35. Jacobs ER, Zhu D, Gruenloh SK, Lopez B, Medhora M. VEGF-induced relaxation of pulmonary arteries is mediated by endothelial cytochrome P450 hydroxylase. Am J Physiol, in press (available online).
36. Muthalif M.M., Benter I.F., Karzoun N., et al. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci USA 95 (1998) 12701-12706
37. Mezentsev A., Merks R.M., O'Riordan E., et al. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol 289 (2005) H1106-H1114
38. Mastyugin V., Mosaed S., Bonazzi A., Dunn M.W., and Schwartzman M.L. Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 23 (2001) 1-10
39. Munzenmaier D.H., and Harder D.R. Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol 278 (2000) H1163-H1167
40. Zhang C., and Harder D.R. Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid. Stroke 33 (2002) 2957-2964
41. Medhora M., Daniels J., Mundey K., et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 284 (2003) H215-H224
42. Medhora M., and Harder D. Functional role of epoxyeicosatrienoic acids and their production in astrocytes: approaches for gene transfer and therapy. Int J Mol Med 2 (1998) 661-669 review
43. Michaelis U.R., Fisslthaler B., Medhora M., Harder D., Fleming I., and Busse R. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 17 (2003) 770-772
44. Potente M., Michaelis U.R., Fisslthaler B., Busse R., and Fleming I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem 277 (2002) 15671-15676
45. Pozzi A., Macias-Perez I., Abair T., et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 280 (2005) 27138-27146
46. Michaelis U.R., Fisslthaler B., Barbosa-Sicard E., Falck J.R., Fleming I., and Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 118 (2005) 5489-5498
47. Wang Y., Wei X., Xiao X., et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 314 (2005) 522-532
48. Zhang B., Cao H., and Rao G.N. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis. J Biol Chem 281 (2006) 905-914
49. Dhanasekaran A, Al-Saghir R, Lopez B, et al. Protective effects of epoxyeicosatrienoic acids (EETs) on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol Heart Circ Physiol, in press (available online).
50. Narayanan J., Mundey K., Sharma M., and Medhora M. Role of cytochrome P450-catalyzed metabolites of arachidonic acid in angiogenesis. Rec Res Dev Physiol 1 Part II (2003) 793-800
51. Fleming I., and Busse R. Endothelium-derived epoxyeicosatrienoic acids and vascular functions. Hypertension 47 (2006) 629-633
52. Haskell H., Natarajan M., Hecker T.P., et al. Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells. Clin Cancer Res 9 (2003) 2157-2165
53. Owen J.D., Ruest P.J., Fry D.W., and Hanks S.K. Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol 19 (1999) 4806-4818
54. Morla A.O., and Mogford J.E. Control of smooth muscle cell proliferation and phenotype by integrin signaling through focal adhesion kinase. Biochem Biophys Res Commun 272 (2000) 298-302
55. Alkayed N.J., Goyagi T., Joh H.D., et al. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack. Stroke 33 (2002) 1677-1684
56. Nithipatikom K., Moore J.M., Isbell M.A., Falck J.R., and Gross G.J. Epoxyeicosatrienoic acids (EETs) in cardioprotection: ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol (2006)
57. Seubert J., Yang B., Bradbury J.A., et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95 (2004) 506-514
58. Dhanasekaran A., Stephanie G., Jacobs E.R., and Medhora M. Epoxyeicosatrienoic acids (EETs) protect cardiovascular cells from apoptosis mediated by caspase 3-dependent pathways. FASEB J 20 (2006) A123
59. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand. VEGF-E. Cancer Sci 94 (2003) 751-756
60. Chen J.K., Capdevila J., and Harris R.C. Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 21 (2001) 6322-6331
61. Wang Y., Yang S., and Wang D.W. Cytochrome P450 epoxygenase-derived lipopolysaccharide-induced apoptosis of endothelial cells. Winter Eicsoanoid Conference (2006) 30
62. Sharma M., Sharma R., McCarthy E.T., and Savin V.J. The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med (Maywood) 229 (2004) 85-98
63. Sharma M., Reddy D.S., Falck J.R., et al. 8,9 EET protects against FSGS Factor-Induced glomerular injury. Winter Eicosanoid Conference (2006) 27
64. Dunn L.K., Gruenloh S.K., Dunn B.E., et al. Chick chorioallantoic membrane as an in vivo model to study vasoreactivity: characterization of development-dependent hyperemia induced by epoxyeicosatrienoic acids (EETs). Anat Rec A Discov Mol Cell Evol Biol 285 (2005) 771-780
65. Cowart L.A., Wei S., Hsu M.H., et al. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 277 (2002) 35105-35112